Kinnate Biopharma is a biopharmaceutical company advancing a pipeline of precision oncology therapeutics to treat patients with genomically defined vulnerabilities.
At Kinnate we design and develop selective small molecules with the mission
to provide the right drug to the right patient.
Program 1 is a first-in-class precision oncology opportunity focused on DNA damage repair mechanisms.
Program 2 is a next generation inhibitor targeting gene rearrangements with known resistance mutations.
Program 3 is a best-in-class inhibitor targeting a pathway clinically validated across all cancers.
Our team of oncology experts all have decades of experience
in successfully developing small molecule therapies.
Steve Kaldor, Ph.D.
CEO and Co-founder
View Bio >
Eric Murphy, Ph.D.
CSO and Co-founder
View Bio >
Sailash Patel, Pharm.D.
COO
View Bio >
A diverse blend of experience in pharmaceutical R&D,
business development and life sciences investing.
Steve Kaldor, Ph.D.
Fount Therapeutics
View Bio >
Eric Murphy, Ph.D.
Fount Therapeutics
View Bio >
Jim Tananbaum, MD
Foresite Capital
View Bio >
Fred Eshelman, Ph.D.
Eshelman Ventures
View Bio >
A unique pairing of world-class precision medicine oncology leaders and
clinical researchers from leading institutions.
Keith Flaherty, MD
Mass General Hospital
View Bio >
Ryan Corcoran, MD PhD
Mass General Hospital
View Bio >
David Hyman, MD
MSK
View Bio >
Ezra Cohen, MD
Moores Cancer Center
View Bio >
Andrew Lowy, MD
Moores Cancer Center
View Bio >
April 2018
Fount Therapeutics secures $22 million Series A financing from Foresite Capital and Eshelman Ventures. The funds will establish multiple subsidiary R&D companies to develop treatments in various therapeutic areas. The first "NewCo", Kinnate, will be focused on developing precision oncology treatments. Other companies soon to follow.